DEVELOPING INNOVATIVE APPROACHES TO USE HUMAN DATA TO DISCOVER AND VALIDATE NEW TARGETS
Advances in genomics have led to the creation of huge data sets that can uncover the details of biological processes involved in human health and disease. Despite these advances, drug discovery and development remains a time-consuming, high-risk and incredibly difficult process, with a worryingly small success rate.
Many of the answers to the challenges in this process remain locked inside the data. The efficiency and innovation gap in drug development needs to be addressed through innovative approaches, to dramatically increase the success rate of lead generation for drug discovery and help build a more robust drug discovery pipeline.
ATTENDEES CONFIRMED (SO FAR):
Chris Miller, Director of Drug Discovery, AbbVie
Matt Nelson, Head of Genetics, GSK
Aaron Day-Williams, Director of Quantitative Target Sciences, Merck
Diane Joseph-McCarthy, Vice President, Translational Science, Enbiotix
Bin Li, Director of Computational Biology, Takeda
Vibhor Gupta, Director, Pangaea Group
Gautham Sridharan, Research Scientist, Alnylam Pharmaceuticals
Leila Pirhaji, Founder and CEO, ReviveMed
Sharon Shechter, Principal Investigator, Silicon Therapy
Ping Zhu, Head of Target Discovery and Genomics, H3 Biomedicine
Joel Klappenbach, Director, Genome Sciences, Merck
Ken Rhodes, CSO, Yumanity Therapeutics
Agustin Chicas, Head of Genomic Target Discovery and Validation, Forma Therapeutics
Hans Winkler, Independent Consultant
POINTS OF DISCUSSION:
Emerging technologies and software solutions, including AI/ML, that can benefit the drug development pipeline by eliminating bias and accessing vast amounts of multi-parameter data.
A need for guidelines to establish what is a truly validated drug target, and to remove any disconnect between industry and academia.
Applying existing technologies and methods to data available in the public domain to discover new targets in a systematic way.
Identifying and overcoming barriers to human translation and functional testing.
MEETING OUTPUT:
Identification of the most beneficial emerging technologies, and a summary of common trends among the innovation efforts of meeting participants.
Actions to overcome the limitations of functional testing and analysis of publicly available data.
Potential guidelines to define a validated drug target.
Opportunities for collaboration and open innovation for improvement of the drug development pipeline.